A strange case of severe but fleeting hypoxemia in patient with COVID-19 infection: maybe virus-induced pulmonary Raynaud’s phenomenon?

Submitted: November 28, 2020
Accepted: January 8, 2021
Published: March 5, 2021
Abstract Views: 829
PDF: 422
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


This case-report describes severe acute respiratory failure in a patient with a COVID-19 positive nasopharyngeal swab that spontaneously resolved within a few hours. It is speculated that the virus may have caused a fleeting pulmonary vasospasm.



PlumX Metrics


Download data is not yet available.


Lombardy Region. Official Bulletin March 18th, 2020. Available from: https://www.open.online/2020/03/18/coronavirus-bollettino-regione-lombardia-18-marzo
Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med 2020;8:1201-8. DOI: https://doi.org/10.1016/S2213-2600(20)30370-2
Bunce PE, High SM, Nadjafi M, et al. Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 2011;52:e14-7. DOI: https://doi.org/10.1093/cid/ciq125
O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax 2017;72:i1-i90. DOI: https://doi.org/10.1136/thoraxjnl-2016-209729
Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11:554-9.
Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993;150:4601-9.
Palazzini M, Manes A, Negro L, et al. Pulmonary arterial hypertension. Part I: pathobiologic, pathophysiologic, clinical and diagnostic aspects. G Ital Cardiol 2009;10:271-300.
Jung F, Krüger-Genge A, Franke RP, et al. COVID-19 and the endothelium. Clin Hemorheol Microcirc 2020;75:7-11. DOI: https://doi.org/10.3233/CH-209007
Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65. DOI: https://doi.org/10.1161/01.CIR.0000102381.57477.50
Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54. DOI: https://doi.org/10.1016/S0002-9343(99)80156-9
Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-46. DOI: https://doi.org/10.1172/JCI17500
Teman NR, Thomas J, Bryner BS, et al. Inhaled nitric oxide to improve oxygenation for safe critical care transport of adults with severe hypoxemia. Am J Crit Care 2015;24:110-7. DOI: https://doi.org/10.4037/ajcc2015570
Akerström S, Gunalan V, Keng CT, et al. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology 2009;395:1-9. DOI: https://doi.org/10.1016/j.virol.2009.09.007
Chen L, Liu P, Gao H, et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis 2004;39:1531-5. DOI: https://doi.org/10.1086/425357
Adusumilli NC, Zhang D, Friedman JM, Friedman AJ. Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19. Nitric Oxide 2020;103:4-8. DOI: https://doi.org/10.1016/j.niox.2020.07.003

How to Cite

Barbarito, Nicola. 2021. “A Strange Case of Severe But Fleeting Hypoxemia in Patient With COVID-19 Infection: Maybe Virus-Induced Pulmonary Raynaud’s Phenomenon?”. Monaldi Archives for Chest Disease 91 (2). https://doi.org/10.4081/monaldi.2021.1706.